First Patient Enrolled in Revita® Wound Care Study


We’re excited to announce the commencement of our second level 1 clinical study for Revita!

This level 1 randomized controlled trial will assess the safety and efficacy of Revita as a wound covering for diabetic foot ulcers (DFUs). Diabetes impacts 30 million people across the United States, and as many as 25% of diabetic patients will develop a DFU within their lifetime.1-2 Without proper treatment, DFUs commonly result in amputation, leaving the patient with a 50% chance of survival. 3-4

As the first placental membrane allograft to capture the complete intact membrane in a shelf-stable format, Revita is uniquely capable of addressing DFUs. Since the product was launched, Revita has shown excellent effectiveness as a wound covering for a broad range of wound types including DFUs. This study will build on that experience and demonstrate broader, clinically validated outcomes.

We are thrilled to have this trial underway and are continuing to invest in high quality outcomes data for the complete portfolio of StimLabs products.

More information on this study can be found press release.

MKTG 19- 004 Rev 01

1. American Diabetes Association. Statistics About Diabetes. 2018 Mar.2. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA2005;293:217–228pmid:1564454.3. Alexiadou, Management of Diabetic Foot Ulcers. 2012 Apr 20.4. Armstrong DG, Wrobel J, Robbins JM. Guest editorial: are diabetes-related wounds and amputations worse than cancer? Int Wound J 2007;4:286–287pmid:18154621

Why create a blog?

We want to share our perspective and establish an open line of communication with clinicians, scientists, patients and more. We’ll be using this blog as a forum for a few different topics.

1. Corporate Updates

Being new and different requires clarity. As our first two products have redefined what’s possible with placental tissue, we’ve found the need to have a forum for company updates.

2. Scientific Clarity

The new world of regenerative medicine is largely unexplored. As a result, there is a lot of conflicting information about the science behind products. Our Product Development team has spent their careers researching and developing new technologies, and we want to share some of the information they’ve gathered.

3. Product Updates

We move quickly with new initiatives. Within a year of founding StimLabs, we brought Revita to market, and just a few months later, we brought Ascent to market. As you’ll learn in our next post, we’re plotting a course for even more ambitious products, and our current offerings are just the beginning.

We’re excited about the future, and are looking forward to an open dialogue with the scientific and clinical communities about products that will have a lasting impact on patient care.

MKTG 18-008 Rev 01